On the other hand, a member of the Eph family of receptors, EphA2, was shown to be a relevance biomarker in SCC, where it promotes invasion, cell motility, and angiogenesis through the activation of Src [87, 88]. EphA2 mutations are rare in NSCLC but are mainly present in SCC [89]. The gene discussed is EPHA2; the disease is non-small cell lung carcinoma.